Juno Therapeutics Inc. (JUNO) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Juno Therapeutics Inc. (JUNO)

JUNO 86.96

0.0%

Mar 6 4:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: Julius Wong	8/28/2017 7:55:05 AM
	of 84

Gilead - Kite deal stokes buying in Juno Therapeutics, up 8% premarket CAR-T developer Therapeutics (NASDAQ: JUNO) is up 8% premarket, albeit on only 1,100 shares, on the heels of Gilead's $11B takeout of Kite Pharma. Juno sued Kite over its U.S. Patent No. 7,446,190 covering a construct for a CD-19-targeted CAR T cell treatment that employs a CD28 costimulatory domain claiming axicabtagene ciloleucel infringed. In December 2016, the USPTO agreed with Juno. The ruling is under appeal.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next